National Perinatal Association 2018 Respiratory Syncytial Virus (RSV) Prevention Clinical Practice Guideline: An Evidence-Based Interdisciplinary Collaboration-Reference-Cited by-同舟云学术

National Perinatal Association 2018 Respiratory Syncytial Virus (RSV) Prevention Clinical Practice Guideline: An Evidence-Based Interdisciplinary Collaboration

Published:2017 Issue:10 Volume:12 Page:1-14
ISSN:1932-7137
Container-title:Neonatology Today
language:en
Short-container-title:Neonatology Today

Author:

Goldstein Mitchell¹,Philips Raylene¹,DeVincenzo John²,Krilov Leonard³,Merritt T. Allen¹,Yogev Ram⁴,Staebler Suzanne⁵,Kadri Munaf¹,Fergie Jaimie⁶,Schechter Michael⁷,Gorham Millicent⁸,Cherry James⁹

Affiliation:

1. Loma Linda University School of Medicine

2. University of Tennessee Center for Health Sciences

3. State University of New York Stony Brook

4. Northwestern University Feinberg School of Medicine

5. Emory University Nell Hodgson Woodruff School of Nursing

6. Texas A&M College of Medicine

7. Virginia Commonwealth University

8. National Black Nurses Association

9. University of California, Los Angeles

Publisher

Loma Linda Publishing Company

Subject

General Medicine

Reference144 articles.

1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545-55. Level II-2 (A)

2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095-128. Level II-2 (A)

3. From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124(6):1694-701.Level II-1 (A)

4. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112(6 Pt 1):1442-6.Level II-2 (A)

5. Krilov LR, Weiner LB, Yogev R, Fergie J, Katz BZ, Henrickson KJ, et al. The 2009 COID recommendations for RSV prophylaxis: issues of efficacy, cost, and evidence-based medicine. Pediatrics. 2009;124(6):1682-4.Level II-3 (A)

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Palivizumab in Preventing Severe Acute Lower Respiratory Infection in Moderate-to-Late Preterm Infants: A Nationwide Cohort Study;Journal of Korean Medical Science;2024

2. Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral (RSV) disease in high‐risk infants;Pediatric Pulmonology;2023-02-14

3. Respiratory Syncytial Virus;Emerging Human Viral Diseases, Volume I;2023

4. New strategies for the prevention of respiratory syncytial virus (RSV);Early Human Development;2022-11

5. Real-World Studies of Respiratory Syncytial Virus Hospitalizations among Moderate/Late Preterm Infants Exposed to Passive Immunoprophylaxis with Palivizumab;American Journal of Perinatology;2022-10-28